Unicycive Therapeutics, Inc. (UNCY)

$0.73

+0.00 (+0.21%)
Rating:
Recommendation:
-
Symbol UNCY
Price $0.73
Beta 0.000
Volume Avg. 0.03M
Market Cap 11.015M
Shares () -
52 Week Range 0.511-2.35
1y Target Est -
DCF Unlevered UNCY DCF ->
DCF Levered UNCY LDCF ->
ROE -139.91% Strong Sell
ROA -152.13% Strong Sell
Operating Margin -
Debt / Equity 120.00% Buy
P/E -0.77
P/B 2.38 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest UNCY news


Dr. Shalabh K. Gupta
Healthcare
Biotechnology
NASDAQ Capital Market

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.